Gilead Sciences Could Be in For a Share Slump

TheStreet's Adam Feuerstein says shares of Gilead Sciences' (GILD) - Get Report may appear to be at a discounted price, but may be a value trap as investors grow frustrated after two years of stagnant growth. Feuerstein noted Gilead CEO John Milligan may be at risk of losing his position as one of biotech's 'best, most trusted' CEOs. Piper Jaffray biotech analyst Josh Schimmer says, 'Investors have broadly lost confidence in management's ability to navigate the future competitive landscapes for its businesses and create value.' Real Money recently reported that Gilead may be better off spinning off some of its drug businesses to unlock value, and shares are down 23% so far on the year.

Employees of TheStreet are restricted from owning individual securities.